Stay updated with breaking news from Eric Dobmeier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
/cloudfront-us-east-1.images.arcpublishing.com/tgam/QG5A5UDORBNI7E7VWZSVDL7XYQ.jpg)
Swiss drug giant will pay US$40 a share for Chinook; shareholders could receive an additional US$4 a share if further milestones are reached
:max_bytes(150000):strip_icc()/GettyImages-1451737630-675fde06632049f68ccca63df9d8c94b.jpg)
Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion.
Novartis announced June 12 that it will acquire Chinook Therapeutics, a Seattle-based biopharmaceutical company, for a total value of $3.5 billion.
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond...